Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis.

An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):242-249.

View in: PubMed

© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.